Skip to main content

Table 5 Univariable and multivariable logistic regression on the risk of malaria pigment deposition in the placenta

From: Pregnancy outcomes and risk of placental malaria after artemisinin-based and quinine-based treatment for uncomplicated falciparum malaria in pregnancy: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis

Baseline characteristicProportion (%)UnivariableMultivariable
OR (95% CI)p valueaOR (95% CI)p value
Treatment
 AL733/880 (83%)Reference Reference 
 AS56/84 (67%)1.63 (0.86–3.10)0.131.77 (0.85–3.68)0.13
 ASAQ544/645 (84%)0.93 (0.67–1.29)0.680.90 (0.63–1.28)0.55
 ASMQ560/658 (85%)0.80 (0.57–1.12)0.200.78 (0.54–1.13)0.20
 DP559/642 (87%)0.96 (0.67–1.36)0.810.91 (0.62–1.34)0.64
 Q53/78 (68%)1.05 (0.55–2.00)0.890.80 (0.38–1.66)0.55
Interval from malaria to delivery (week)2505/2987 (84%)0.98 (0.96–0.99)0.0050.97 (0.95–0.99)0.002
Age (year)2505/2987 (84%)0.89 (0.88–0.91)< 0.0010.93 (0.91–0.95)< 0.001
Parity
 01199/1292 (93%)Reference Reference 
 1498/580 (86%)0.50 (0.36–0.69)< 0.0010.82 (0.58–1.17)0.27
 ≥ 2807/1112 (73%)0.21 (0.16–0.27)< 0.0010.59 (0.41–0.86)0.006
Weight (kg)2505/2987 (84%)0.97 (0.96–0.98)< 0.001  
Height (cm)2383/2806 (85%)0.98 (0.96–1.00)0.01  
BMI (kg/m2)2383/2806 (85%)0.95 (0.92–0.99)0.008  
HIV infection
 Yes18/24 (75%)1.06 (0.40–2.82)0.91  
 No2035/2414 (84%)Reference   
Parasitaemia (log10/μL)2505/2987 (84%)2.04 (1.76–2.35)< 0.0011.67 (1.42–1.96)< 0.001
Body temperature (°C)2504/2986 (84%)1.35 (1.13–1.61)< 0.0011.22 (1.00–1.49)0.045
Haemoglobin (g/dL)2500/2978 (84%)0.65 (0.60–0.70)< 0.0010.72 (0.65–0.78)< 0.001
Gametocytaemia
 Yes84/91 (92%)3.60 (1.62–7.97)0.0023.62 (1.58–8.26)0.002
 No2417/2891 (84%)Reference Reference 
Mixed infection
 Yes12/16 (75%)1.82 (0.57–5.82)0.31  
 No2493/2971 (84%)Reference   
Malaria transmission
 Low159/249 (64%)1.16 (0.57–2.34)0.690.81 (0.34–1.91)0.63
 Moderate1588/1838 (86%)Reference Reference 
 High758/900 (84%)1.14 (0.66–1.96)0.651.16 (0.63–2.13)0.64
  1. Intraclass correlation, 0.14. AL artemether-lumefantrine, aOR adjusted odds ratio, AS artesunate monotherapy, ASAQ artesunate-amodiaquine, ASMQ artesunate-mefloquine, BMI body mass index, CI confidence interval, DP dihydroartemisinin-piperaquine, EGA estimated gestational age, G gravidity, HIV human immunodeficiency virus, OR odds ratio, Q quinine monotherapy